The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry

BACKGROUND: The impact of immune-modifying therapies on outcomes of coronavirus disease 2019 [COVID-19] is variable. The purpose of this study was to determine the impact of vedolizumab [VDZ], a gut-selective anti-integrin, on COVID-19 outcomes in inflammatory bowel disease [IBD] patients. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Agrawal, Manasi, Zhang, Xian, Brenner, Erica J, Ungaro, Ryan C, Kappelman, Michael D, Colombel, Jean-Frederic
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8083188/
https://www.ncbi.nlm.nih.gov/pubmed/33884425
http://dx.doi.org/10.1093/ecco-jcc/jjab071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8083188/
https://www.ncbi.nlm.nih.gov/pubmed/33884425
http://dx.doi.org/10.1093/ecco-jcc/jjab071

Ejemplares similares